ClinicalTrials.gg
TerminatedNCT03834493Updated Sep 28, 2026Results posted

Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

A Phase 3 interventional study of Pembrolizumab and Enzalutamide in Prostatic Neoplasms, sponsored by Merck Sharp & Dohme LLC. Terminated at 259 sites in 28 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
The study stopped due to futility
Updated Sep 28, 2026Now TerminatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,244
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing pembrolizumab in Prostatic Neoplasms — 4 open to participants now, 8 under way, none of them phase 3. pembrolizumab · Prostatic Neoplasms.

Enrollment
Largest of 20
1,244 · median 41
Started
2019
with 3 others
Phase 3
4 of 20
none open now
Registered
9th of 20
by date
Lead sponsor
5 of 20
Merck Sharp & Dohme LLC

Among the 20 studies testing pembrolizumab in Prostatic Neoplasms, this one has the largest enrollment, is one of 4 that started in 2019, is one of 4 in phase 3, and was the 9th registered.

Prostatic Neoplasms

7,052 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 20 studies testing pembrolizumab in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About pembrolizumab

pembrolizumab: first FDA approval 2014 (KEYTRUDA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing pembrolizumab in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC, are abiraterone-naïve, or are intolerant to or progressed on abiraterone acetate. There are two primary study hypotheses.

Hypothesis 1: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Overall Survival (OS).

Hypothesis 2: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Radiographic Progression-free Survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review.

03

Conditions studied

  • Prostatic Neoplasms

Browse trials for

Keywords

  • Programmed Cell Death-1 (PD1, PD-1)
  • Programmed Death-Ligand 1 (PDL1, PD-L1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion criteria

Inclusion Criteria:

  • Has - or cytologically-confirmed adenocarcinoma of the prostate without small cell histology
  • Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months prior to randomization
  • Has current evidence of disease documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI)
  • Has met one of the following criteria with regard to abiraterone acetate exposure: (1) is abiraterone-naïve; (2) received prior abiraterone acetate for the treatment of mHSPC or mCRPC, for a minimum of 4 weeks and not progressed while on treatment; or (3) received prior abiraterone acetate for the treatment of mHSPC or mCRPC and progressed on treatment after a minimum of 8 weeks treatment (minimum 14 weeks for those with bone progression)
  • Has ongoing androgen deprivation with serum testosterone \<50 ng/dL (\<2.0 nM)
  • Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses prior to randomization
  • Participants must agree to the following during the study treatment period and for at least 90 days after the last dose of enzalutamide: Refrain from donating sperm, plus EITHER be abstinent OR must agree to use male condom
  • Has provided newly obtained core or excisional (obtained within 12 months of screening) from soft tissue not previously irradiated (samples from tumors progressing in a prior site of radiation are allowed). Participants with bone only or bone predominant disease may provide a bone biopsy sample
  • Has an (ECOG) performance status of 0 or 1 assessed within 7 days of randomization

Exclusion criteria

Exclusion Criteria:

  • Has a known additional that is progressing or has required active treatment in the last 3 years
  • Has an active disease that has required systemic treatment in past 2 years
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy
  • Has undergone major surgery including local prostate intervention (excluding prostate ) within 28 days prior to randomization and not recovered adequately from the toxicities and/or complications
  • Has a gastrointestinal disorder affecting absorption or is unable to swallow tablets/capsules
  • Has an active infection (including tuberculosis) requiring systemic therapy
  • Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease
  • Has known active (HIV), concurrent active virus (HBV) or known active virus (HCV) infection
  • Has known active central nervous system (CNS) and/or carcinomatous meningitis
  • Has to pembrolizumab and/or enzalutamide and/or any of their
  • Has a history of seizure or any condition that may predispose to seizure
  • Has a history of loss of consciousness within 12 months of screening
  • Has hypotension (systolic blood pressure \<86 millimeters of mercury [mmHg]) or uncontrolled hypertension (systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg) at the screening visit
  • Has bradycardia (heart rate of \<50 beats per minute) on the screening (ECG)
  • Has history of prostate cancer progression on ketoconazole
  • Has had prior treatment with enzalutamide, apalutamide, darolutamide or cytochrome P450 (CYP) 17 inhibitor other than abiraterone acetate
  • Has received prior therapy with an anti-programmed cell death-1 (), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor
  • Has received prior treatment with radium or other therapeutic radiopharmaceuticals for prostate cancer
  • Has received prior treatment with docetaxel or another chemotherapy agent for mCRPC
  • Has had a prior anti-cancer monoclonal antibody (mAb) prior to randomization
  • Has used herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (eg, saw palmetto) prior to randomization
  • Has received a live or within 30 days prior to randomization
  • Is currently participating in or has participated in a study of an agent or has used an investigational device within 4 weeks prior to the first dose of study treatment
  • Has a "superscan" bone scan
  • Is expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 90 days after the last dose of enzalutamide
  • Has had an allogenic tissue/solid organ transplant
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,244 participants (actual)

Study arms

  • Experimental
    Pembrolizumab + Enzalutamide

    Participants receive 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered orally (PO) once a day (QD) continuously until progression.

    Biological: Pembrolizumab · Drug: Enzalutamide

  • Placebo comparator
    Placebo + Enzalutamide

    Participants receive placebo by IV infusion administered on Day 1 Q3W for up to 35 cycles (approximately 2 years) PLUS enzalutamide 160 mg administered PO QD continuously until progression.

    Drug: Enzalutamide · Drug: Placebo

Interventions

  • BiologicalPembrolizumab

    IV infusion

    Also known as: KEYTRUDA®, MK-3475

  • Capsules/Tablets

    Also known as: XTANDI®

  • DrugPlacebo

    IV infusion

    Also known as: Normal saline or dextrose infusion

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause. The OS for all participants is presented.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  2. Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review

    rPFS was defined as the time from randomization to the first documented progressive disease (PD) per PCWG-modified RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurred first. The rPFS per PCWG-modified RECIST for all participants is presented.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

Secondary outcomes

  1. Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)

    TFST was defined as time from randomization to initiation of the first subsequent anti-cancer therapy or death, whichever occurs first. The TFST for all participants is presented.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  2. Prostate-specific Antigen (PSA) Response Rate

    PSA response rate was defined as percentage of participants in the analysis population who have a negative change (decrease) in PSA level of ≥50% measured twice ≥3 weeks apart. The analysis was performed on participants who had baseline PSA measurements.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  3. Prostate-specific Antigen (PSA) Undetectable Rate

    PSA undetectable rate was defined as percentage of participants in the analysis population with PSA \<0.2 ng/mL during study treatment. The analysis was performed on participants who had baseline PSA measurements.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  4. Objective Response (OR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review

    OR was defined as the percentage of participants with complete response (CR: disappearance of all target lesions per RECIST 1.1; and no evidence of disease (NED) on bone scan per PCWG) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions per RECIST 1.1; and non-progressive disease, non-evaluable \[NE\], or NED on bone scan or CR with non-progressive disease or NE bone scan per PCWG).

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  5. Duration of Response (DOR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review

    DOR was defined as the time from first documented evidence of complete response (CR) or partial response (PR) per PCWG and RECIST 1.1 criteria until progressive disease (PD) or death. PD per RECIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD per PCWG was the appearance of ≥2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and were persistent for ≥6 weeks. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data. If a participant had not progressed, the participant was censored at the date of last disease assessment.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  6. Time to Prostate-specific Antigen (PSA) Progression

    Time from randomization to PSA progression. PSA progression date is defined as the date of 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, or 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  7. Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review

    Time from randomization to radiographic soft tissue progression per PCWG-modified RECIST 1.1

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  8. Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and Opiate Analgesic Use (Analgesic Quantification Algorithm [AQA] Score)

    Time from randomization to pain progression. In this study, pain progression was assessed by participant responses to Item 3 of the BPI-SF and participant AQA Scores which are both assessed by participants daily for 7 consecutive days.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  9. Time to First Symptomatic Skeletal-related Event (SSRE)

    Time from randomization to the first SSRE. SSRE is defined as radiation to prevent or relieve skeletal symptoms, occurrence of new symptomatic pathological fracture, spinal cord compression, or surgery to bone.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  10. Number of Participants Who Experience an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. The number of participants who experienced an AE is presented.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

  11. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)

    An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. The number of participants who discontinued study treatment due to an AE is presented.

    Time frame: Up to 40 months (through database cut-off date of 12-Dec-2022)

07

Results

Posted Dec 20, 2023

Participant flow

Participant flow — Overall Study
MilestonePembrolizumab + EnzalutamidePlacebo + Enzalutamide
Started621623
Treated615620
Completed00
Not completed621623
Withdrew: Participants ongoing311324
Withdrew: Withdrawal by subject2017
Withdrew: Physician decision10
Withdrew: Death289282

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause. The OS for all participants is presented.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Median · Months
Overall Survival (OS)
MonthsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Overall Survival (OS)24.7 (22.0 to 26.8)27.3 (24.5 to 30.1)
Statistical analysis
  • Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide · Log Rank · p = 0.6621 · Hazard ratio (hr): 1.04 · 95% CI 0.88 to 1.22Stratified Cox model with Efron's tie handling method
PrimaryRadiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review

rPFS was defined as the time from randomization to the first documented progressive disease (PD) per PCWG-modified RECIST 1.1 based on blinded independent central review or death due to any cause, whichever occurred first. The rPFS per PCWG-modified RECIST for all participants is presented.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Median · Months
Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review
MonthsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review10.4 (8.4 to 12.5)9.0 (8.3 to 11.5)
Statistical analysis
  • Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide · Log Rank · p = 0.4073 · Hazard ratio (hr): 0.98 · 95% CI 0.84 to 1.14Stratified Cox model with Efron's tie handling method
SecondaryTime to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)

TFST was defined as time from randomization to initiation of the first subsequent anti-cancer therapy or death, whichever occurs first. The TFST for all participants is presented.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Median · Months
Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)
MonthsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Time to Initiation of the First Subsequent Anti-cancer Therapy or Death (TFST)13.2 (11.7 to 15.7)12.6 (11.3 to 14.2)
Statistical analysis
  • Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide · Hazard ratio (hr): 0.95 · 95% CI 0.83 to 1.09Stratified Cox model with Efron's tie handling method
SecondaryProstate-specific Antigen (PSA) Response Rate

PSA response rate was defined as percentage of participants in the analysis population who have a negative change (decrease) in PSA level of ≥50% measured twice ≥3 weeks apart. The analysis was performed on participants who had baseline PSA measurements.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Number · Percentage of participants
Prostate-specific Antigen (PSA) Response Rate
Percentage of participantsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Prostate-specific Antigen (PSA) Response Rate49.0 (44.9 to 53.1)45.1 (41.1 to 49.2)
Statistical analysis
  • Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide · Difference in percentage: 3.4 · 95% CI -1.5 to 8.3Stratified Miettinen and Nurminen method
SecondaryProstate-specific Antigen (PSA) Undetectable Rate

PSA undetectable rate was defined as percentage of participants in the analysis population with PSA \<0.2 ng/mL during study treatment. The analysis was performed on participants who had baseline PSA measurements.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Number · Percentage of participants
Prostate-specific Antigen (PSA) Undetectable Rate
Percentage of participantsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Prostate-specific Antigen (PSA) Undetectable Rate13.1 (10.5 to 16.1)12.6 (10.0 to 15.5)
Statistical analysis
  • Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide · Difference in percentage: 0.3 · 95% CI -3.4 to 4.1Stratified Miettinen and Nurminen method
SecondaryObjective Response (OR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review

OR was defined as the percentage of participants with complete response (CR: disappearance of all target lesions per RECIST 1.1; and no evidence of disease (NED) on bone scan per PCWG) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions per RECIST 1.1; and non-progressive disease, non-evaluable \[NE\], or NED on bone scan or CR with non-progressive disease or NE bone scan per PCWG).

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Number · Percentage of participants
Objective Response (OR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review
Percentage of participantsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Objective Response (OR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review12.2 (9.8 to 15.1)9.3 (7.1 to 11.9)
Statistical analysis
  • Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide · Difference in percentage: 2.9 · 95% CI -0.2 to 6.1Stratified Miettinen and Nurminen method
SecondaryDuration of Response (DOR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review

DOR was defined as the time from first documented evidence of complete response (CR) or partial response (PR) per PCWG and RECIST 1.1 criteria until progressive disease (PD) or death. PD per RECIST 1.1 was defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. PD per PCWG was the appearance of ≥2 new bone lesions on bone scan, that have been confirmed to not represent tumor flare, and were persistent for ≥6 weeks. The DOR was calculated using the product-limit (Kaplan-Meier) method for censored data. If a participant had not progressed, the participant was censored at the date of last disease assessment.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Median · Months
Duration of Response (DOR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review
MonthsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Duration of Response (DOR) Per Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review16.1 (1.4 to 35.3)21.5 (0.0 to 35.3)
SecondaryTime to Prostate-specific Antigen (PSA) Progression

Time from randomization to PSA progression. PSA progression date is defined as the date of 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline, or 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Median · Months
Time to Prostate-specific Antigen (PSA) Progression
MonthsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Time to Prostate-specific Antigen (PSA) Progression6.4 (5.5 to 7.1)5.6 (4.9 to 6.9)
Statistical analysis
  • Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide · Hazard ratio (hr): 0.99 · 95% CI 0.86 to 1.15Stratified Cox model with Efron's tie handling method
SecondaryTime to Radiographic Soft Tissue Progression Per Soft Tissue Rules of Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review

Time from randomization to radiographic soft tissue progression per PCWG-modified RECIST 1.1

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Median · Months
Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review
MonthsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Time to Radiographic Soft Tissue Progression Per Soft Tissue Rules of Prostate Cancer Working Group (PCWG)-Modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by as Assessed by Blinded Independent Central Review20.7 (18.0 to 30.1)26.3 (17.8 to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide · Hazard ratio (hr): 0.90 · 95% CI 0.74 to 1.09Stratified Cox model with Efron's tie handling method
SecondaryTime to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and Opiate Analgesic Use (Analgesic Quantification Algorithm [AQA] Score)

Time from randomization to pain progression. In this study, pain progression was assessed by participant responses to Item 3 of the BPI-SF and participant AQA Scores which are both assessed by participants daily for 7 consecutive days.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Median · Months
Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and Opiate Analgesic Use (Analgesic Quantification Algorithm [AQA] Score)
MonthsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Time to Pain Progression (TTPP) as Assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and Opiate Analgesic Use (Analgesic Quantification Algorithm [AQA] Score)NA (23.3 to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide · Hazard ratio (hr): 1.05 · 95% CI 0.82 to 1.35Stratified Cox model with Efron's tie handling method
SecondaryTime to First Symptomatic Skeletal-related Event (SSRE)

Time from randomization to the first SSRE. SSRE is defined as radiation to prevent or relieve skeletal symptoms, occurrence of new symptomatic pathological fracture, spinal cord compression, or surgery to bone.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Median · Months
Time to First Symptomatic Skeletal-related Event (SSRE)
MonthsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Time to First Symptomatic Skeletal-related Event (SSRE)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Pembrolizumab + Enzalutamide vs Placebo + Enzalutamide · Hazard ratio (hr): 1.13 · 95% CI 0.85 to 1.51Stratified Cox model with Efron's tie handling method
SecondaryNumber of Participants Who Experience an Adverse Event (AE)

An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. The number of participants who experienced an AE is presented.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Count of participants · Participants
Number of Participants Who Experience an Adverse Event (AE)
ParticipantsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Number of Participants Who Experience an Adverse Event (AE)594596
SecondaryNumber of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)

An AE is defined as any untoward medical occurrence associated with the use of a drug in a participant, whether or not considered drug related. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product and does not imply any judgment about causality. The number of participants who discontinued study treatment due to an AE is presented.

Time frame:
Up to 40 months (through database cut-off date of 12-Dec-2022)
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)
ParticipantsPembrolizumab + EnzalutamidePlacebo + Enzalutamide
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)11550

Adverse events

Collected over Up to 40 months (through database cut-off date of 12-Dec-2022). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pembrolizumab + Enzalutamide295/621 (47.5%)238/615 (38.7%)563/615 (91.5%)
Placebo + Enzalutamide291/623 (46.7%)165/620 (26.6%)551/620 (88.9%)
Pembrolizumab + Enzalutamide Second Course1/4 (25%)0/4 (0%)0/4 (0%)
Most frequent serious events
Showing 10 of 270
Most frequent serious events
EventPembrolizumab + EnzalutamidePlacebo + EnzalutamidePembrolizumab + Enzalutamide Second Course
PneumoniaInfections and infestations16/61510/6200/4
Urinary tract infectionInfections and infestations12/61510/6200/4
Spinal cord compressionNervous system disorders9/61511/6200/4
HaematuriaRenal and urinary disorders3/61510/6200/4
PyrexiaGeneral disorders9/6153/6200/4
UrosepsisInfections and infestations8/6153/6200/4
AnaemiaBlood and lymphatic system disorders7/6154/6200/4
COVID-19 pneumoniaInfections and infestations7/6152/6200/4
PneumonitisRespiratory, thoracic and mediastinal disorders7/6151/6200/4
COVID-19Infections and infestations6/6153/6200/4
Most frequent other events
Showing 10 of 38
Most frequent other events
EventPembrolizumab + EnzalutamidePlacebo + EnzalutamidePembrolizumab + Enzalutamide Second Course
FatigueGeneral disorders190/615170/6200/4
ArthralgiaMusculoskeletal and connective tissue disorders149/615128/6200/4
Decreased appetiteMetabolism and nutrition disorders146/615124/6200/4
AnaemiaBlood and lymphatic system disorders141/615103/6200/4
RashSkin and subcutaneous tissue disorders139/61543/6200/4
NauseaGastrointestinal disorders126/615114/6200/4
Back painMusculoskeletal and connective tissue disorders120/615123/6200/4
DiarrhoeaGastrointestinal disorders115/61579/6200/4
ConstipationGastrointestinal disorders113/61590/6200/4
AstheniaGeneral disorders109/61597/6200/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Pembrolizumab + EnzalutamidePlacebo + EnzalutamideTotal
Mean70.6 ± 8.469.9 ± 9.170.3 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Pembrolizumab + EnzalutamidePlacebo + EnzalutamideTotal
Female000
Male6216231244
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pembrolizumab + EnzalutamidePlacebo + EnzalutamideTotal
Hispanic or Latino121126247
Not Hispanic or Latino465466931
Unknown or Not Reported353166
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pembrolizumab + EnzalutamidePlacebo + EnzalutamideTotal
American Indian or Alaska Native81220
Asian8086166
Native Hawaiian or Other Pacific Islander336
Black or African American121022
White505494999
More than one race121325
Unknown or Not Reported156
08

Study locations

259 sites
  • University of South Alabama, Mitchell Cancer Institute ( Site 0065)
    Mobile, Alabama 36604, United States
  • Providence Medical Foundation-Oncology ( Site 0069)
    Fullerton, California 92835, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0081)
    Los Angeles, California 90404, United States
  • University of Colorado Cancer Center ( Site 0022)
    Aurora, Colorado 80045, United States
  • Smilow Cancer Hospital at Yale New Haven ( Site 0038)
    New Haven, Connecticut 06513, United States
  • Moffitt Cancer Center ( Site 0080)
    Tampa, Florida 33612, United States
  • Georgia Cancer Center at Augusta University ( Site 0026)
    Augusta, Georgia 30912, United States
  • Mount Sinai Hospital ( Site 0042)
    Chicago, Illinois 60608, United States
  • Methodist Hospitals. ( Site 0008)
    Merrillville, Indiana 46410, United States
  • Tulane Cancer Center ( Site 0066)
    New Orleans, Louisiana 70112, United States
  • University of Massachusetts Worcester ( Site 0053)
    Worcester, Massachusetts 01655, United States
  • Cancer & Hematology Centers of Western Michigan ( Site 0013)
    Grand Rapids, Michigan 49503, United States
  • Munson Medical Center ( Site 0030)
    Traverse City, Michigan 49684, United States
  • St. Vincent Frontier Cancer Center ( Site 0016)
    Billings, Montana 59102, United States
  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0034)
    Omaha, Nebraska 68130, United States
  • Comprehensive Cancer Centers of Nevada ( Site 0092)
    Las Vegas, Nevada 89169, United States
  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0004)
    Hackensack, New Jersey 07601, United States
  • Associated Medical Professionals of NY ( Site 0060)
    Syracuse, New York 13210, United States
  • W. G. Bill Hefner VA Medical Center ( Site 0029)
    Salisbury, North Carolina 28144, United States
  • Gabrail Cancer Center-Research ( Site 0096)
    Canton, Ohio 44718, United States
  • Tri-State Urologic Services PSC, Inc. ( Site 0094)
    Cincinnati, Ohio 45212, United States
  • University Hospitals Cleveland Medical Center ( Site 0036)
    Cleveland, Ohio 44106, United States
  • Oregon Health Science University ( Site 0031)
    Portland, Oregon 97239, United States
  • Carolina Urologic Research Center ( Site 0070)
    Myrtle Beach, South Carolina 29572, United States
  • Inova Schar Cancer Institute ( Site 0006)
    Fairfax, Virginia 22031, United States
  • Virginia Cancer Institute ( Site 0052)
    Richmond, Virginia 23230, United States
  • Blue Ridge Cancer Care ( Site 0086)
    Roanoke, Virginia 24014, United States
  • Froedtert Hospital & the Medical College of Wisconsin ( Site 0045)
    Milwaukee, Wisconsin 53226, United States
  • Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 1013)
    Berazategui, Buenos Aires B1884BBF, Argentina
  • Organizacion Medica de Investigacion ( Site 1019)
    CABA, Buenos Aires C1015ABO, Argentina
  • Instituto Medico Alexander Fleming ( Site 1010)
    Ciudad Autonoma de Buenos Aires., Buenos Aires C1426ANZ, Argentina
  • Instituto de Investigaciones Clinicas ( Site 1000)
    Mar del Plata, Buenos Aires B7600FZO, Argentina
  • Centro de Diagnostico Urologico ( Site 1008)
    Buenos Aires, Buenos Aires F.D. C1120AAT, Argentina
  • Sanatorio Parque ( Site 1002)
    Rosario, Santa Fe Province S2000DSV, Argentina
  • Instituto de Oncologia de Rosario ( Site 1015)
    Rosario, Santa Fe Province S2000KZE, Argentina
  • Instituto de Investigaciones Metabolicas [Buenos Aires, Argentina] ( Site 1011)
    Buenos Aires, C1012AAR, Argentina
  • Hospital Aleman ( Site 1004)
    Buenos Aires, C1118AAT, Argentina
  • Centro Medico Dra De Salvo ( Site 1018)
    Buenos Aires, C1426ABP, Argentina
  • CEMAIC ( Site 1014)
    Córdoba, X5008HHW, Argentina
  • Centro Oncologico Riojano Integral ( Site 1005)
    La Rioja, F5300COE, Argentina
  • Centro Oncologico de Integracion Regional. COIR ( Site 1007)
    Mendoza, M5500AYB, Argentina
  • St. Vincent's Hospital ( Site 0158)
    Darlinghurst, New South Wales 2010, Australia
  • St George Hospital ( Site 0157)
    Kogarah, New South Wales 2217, Australia
  • Macquarie University ( Site 0151)
    Macquarie University, New South Wales 2109, Australia
  • Port Macquarie Base Hospital ( Site 0153)
    Port Macquarie, New South Wales 2444, Australia
  • Calvary Mater Newcastle ( Site 0148)
    Waratah, New South Wales 2298, Australia
  • Gallipoli Medical Research Ltd ( Site 0149)
    Greenslopes, Queensland 4120, Australia
  • Gold Coast University Hospital ( Site 0150)
    Southport, Queensland 4215, Australia
  • Royal Adelaide Hospital ( Site 0154)
    Adelaide, South Australia 5000, Australia
  • Monash Medical Centre ( Site 0147)
    Clayton, Victoria 3168, Australia
  • Fiona Stanley Hospital ( Site 0162)
    Perth, Western Australia 6150, Australia
  • Ordensklinikum Linz GmbH Elisabethinen ( Site 0373)
    Linz, Upper Austria 4020, Austria
  • Medizinische Universität Wien ( Site 0375)
    Vienna, 1090, Austria
  • Hospital Erasto Gaertner-CEPEP - Pesquisa Clínica ( Site 1036)
    Curitiba, Paraná 81520-060, Brazil
  • Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1032)
    Natal, Rio Grande do Norte 59075-740, Brazil
  • ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 1038)
    Ijuí, Rio Grande do Sul 98700-000, Brazil
  • Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da Pucrs ( Site 1021)
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Centro de Novos Tratamentos Itajai - Clinica de Neoplasias Litoral ( Site 1035)
    Itajaí, Santa Catarina 88301-215, Brazil
  • Hospital de Base de Sao Jose de Rio Preto ( Site 1022)
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • A.C. Camargo Cancer Center ( Site 1026)
    São Paulo, 01509-900, Brazil
  • Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 1040)
    São Paulo, 04014-002, Brazil
  • MHAT Serdika-Second Department of Medical Oncology ( Site 0505)
    Sofia, Sofia (stolitsa) 1301, Bulgaria
  • MHAT Central Hospital ( Site 0503)
    Plovdiv, 4000, Bulgaria
  • Complex Cancer Center Plovdiv-First Medical Oncology Department ( Site 0507)
    Plovdiv, 4004, Bulgaria
  • BC Cancer Victoria-Clinical Trials Unit ( Site 0111)
    Victoria, British Columbia V8R 6V5, Canada
  • Health Sciences North ( Site 0122)
    Greater Sudbury, Ontario P3E 5J1, Canada
  • Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0116)
    Hamilton, Ontario L8V 5C2, Canada
  • Grand River Hospital ( Site 0120)
    Kitchener, Ontario N2G 1G3, Canada
  • Lakeridge Health ( Site 0117)
    Oshawa, Ontario L1G 2B9, Canada
  • Sunnybrook Research Institute ( Site 0108)
    Toronto, Ontario M4N 3M5, Canada
  • Princess Margaret Cancer Centre ( Site 0107)
    Toronto, Ontario M5G 2M9, Canada
  • CISSS de la Monteregie-Centre ( Site 0119)
    Greenfield Park, Quebec J4V 2H1, Canada
  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0106)
    Montreal, Quebec H2X 3E4, Canada
  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0103)
    Québec, Quebec G1J 1Z4, Canada
  • CIUSSS du Bas Saint Laurent - Hopital Regional de Rimouski ( Site 0102)
    Rimouski, Quebec G5L 5T1, Canada
  • CIUSSS de l Estrie - CHUS - Centre Hosp. Univ. Sherbrooke ( Site 0105)
    Sherbrooke, Quebec J1H 5N4, Canada
  • Centro Investigación del Cáncer James Lind ( Site 1041)
    Temuco, Araucania 4800827, Chile
  • Rey y Oreilly Limitada ( Site 1048)
    Temuco, Araucania 4810148, Chile
  • Fundacion Arturo Lopez Perez ( Site 1049)
    Santiago, Region M. de Santiago 7500921, Chile
  • Pontificia Universidad Catolica de Chile ( Site 1047)
    Santiago, Region M. de Santiago 8330024, Chile
  • Bradfordhill ( Site 1044)
    Santiago, Region M. de Santiago 8420383, Chile
  • Oncocentro ( Site 1045)
    Viña del Mar, Valparaiso 2520598, Chile
  • Hospital Pablo Tobon Uribe ( Site 1066)
    Medellín, Antioquia 050034, Colombia
  • Biomelab S A S ( Site 1067)
    Barranquilla, Atlántico 080001, Colombia
  • Clinica de la Costa S.A.S. ( Site 1073)
    Barranquilla, Atlántico 080020, Colombia
  • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1062)
    Bogotá, Bogota D.C. 110311, Colombia
  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1068)
    Valledupar, Cesar Department 200001, Colombia
  • Oncomédica S.A.S ( Site 1057)
    Montería, Departamento de Córdoba 230002, Colombia
  • Clínica Imbanaco S.A.S ( Site 1064)
    Cali, Valle del Cauca Department 760042, Colombia
  • Hemato Oncologos S.A. ( Site 1065)
    Cali, Valle del Cauca Department 760042, Colombia
  • Fakultni Nemocnice u sv. Anny v Brne-Onkologicko-chirurgicke oddeleni ( Site 1303)
    Brno, Brno-mesto 656 91, Czechia
  • Nemocnice AGEL Novy Jicin a.s. ( Site 1304)
    Nový Jičín, Novy Jicin 741 01, Czechia
  • Fakultni nemocnice Olomouc ( Site 1301)
    Olomouc, Olomouc Region 779 00, Czechia
  • C.H. de Saint Quentin ( Site 0481)
    Saint-Quentin, Aisne 02321, France
  • Centre Jean Perrin ( Site 0434)
    Clermont-Ferrand, Auvergne 63011, France
  • Clinique Sainte Anne ( Site 0431)
    Strasbourg, Bas-Rhin 67000, France
  • CHU de Brest -Site Hopital Morvan ( Site 0441)
    Brest, Brittany Region 29200, France
  • CHU Jean Minjoz ( Site 0423)
    Besançon, Doubs 25000, France
  • Institut Bergonie ( Site 0421)
    Bordeaux, Gironde 33076, France
  • Institut Claudius Regaud IUCT Oncopole ( Site 0418)
    Toulouse, Haute-Garonne 31059, France

Showing the first 100 of 259 sites across 28 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Graff JN, Burotto M, Fong PC, Pook DW, Zurawski B, Manneh Kopp R, Salinas J, Bylow KA, Kramer G, Ratta R, Kwiatkowski M, Retz M, Kwak C, Arranz Arija JA, Gurney H, Matsubara N, Villanueva L, Todenhofer T, Liang LW, Todoric J, Imai K, Stenzl A; KEYNOTE-641 Investigators. Pembrolizumab plus enzalutamide versus placebo plus enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer: the randomized, double-blind, phase III KEYNOTE-641 study. Ann Oncol. 2025 Aug;36(8):976-987. doi: 10.1016/j.annonc.2025.05.007. Epub 2025 May 16. PubMed 40383193 ↗
  • Graff JN, Liang LW, Kim J, Stenzl A. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer. Future Oncol. 2021 Aug;17(23):3017-3026. doi: 10.2217/fon-2020-1008. Epub 2021 May 28. PubMed 34044584 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Dec 2022, 40 months.

Results were first posted in Dec 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2019
First posted
Feb 8, 2019
StartActual
Jul 28, 2019
Primary completionActual
Dec 12, 2022
CompletionActual
Jun 8, 2026
Results first posted
Dec 20, 2023
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Completed→Terminated The study stopped due to futility
changed Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Completed→Terminated
    Why stopped The study stopped due to futility
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03834493
Responsible party
Sponsor
First posted
Feb 8, 2019
Start date
Jul 28, 2019
Primary completion
Dec 12, 2022
Completion
Jun 8, 2026
Results posted
Dec 20, 2023
Last update
Sep 28, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pembrolizumab

Start the discussion